Posts tagged “Chimerix ”
Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.
Chimerix says it has FDA approval to launch a Phase 2 clinical trial of its possible treatment for Ebola. The drug has already been administered to two Ebola patients, one of whom died. The new trial will test safety, tolerability and efficacy for Brincidofovir.
The first Ebola patient diagnosed in the United States died in a Dallas hospital Wednesday, a little more than a week after his illness exposed gaps in the nation's defenses against the disease and set off a scramble to track down anyone exposed to him.
Durham-based Chimerix is providing its experimental antiviral drug to a Dallas patient being treated for Ebola, an emergency step authorized by the Food and Drug Administration. The move came Monday after the FDA authorized Chimerix to accelerate testing of its antiviral treatment.
The Food and Drug Administration is accelerating testing of a potential treatment for the Ebola virus that is being developed by Durham-based Chimerix. Currently there is no cure for the virus, which has killed more than 3,000 people in West Africa.
Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Josh Hardy, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy in March. On Wednesday, his mother said he is doing well and going home.
Durham firm's good FDA news; Chimerix eyes $200M; SEAL Innovation expands; Snapchat adds chat; eBay settles antitrust case
In today's Bulldog blog roundup of technology and life science news, get the latest about drug firm Parion Sciences, a $200 million stock offering from Chimerix, details about Raleigh-based startup SEAL Innovation's expansion, Snapchat finally adds chat, and eBay settles an antitrust case.
A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.
Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Virginia child, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy, the company said Tuesday evening.
Quintiles led the class of Triangle IPOs in the last year at nearly $1 billion in value, but ChannelAdvisor's stock is showing remarkable strength. So is Aerie Pharmaceuticals. With Scynexis filing to go public Thursday, WRALTechWire updates what has happened on the stock "exit route" for regional firms and how their stocks have fared since.
Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.